BLX 0209
Alternative Names: BLX-0209Latest Information Update: 30 Jun 2023
At a glance
- Originator Biolexis Therapeutics
- Class Antidementias
- Mechanism of Action HDAC6 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis
Most Recent Events
- 27 Jun 2023 BLX 0209 is available for licensing as of 27 Jun 2023. https://www.bisichem.com/default/#vision
- 20 Jun 2023 Preclinical trials in Alzheimer's disease in USA (unspecified route) before June 2023 (Biolexis Therapeutics pipeline, June 2023)
- 20 Jun 2023 Preclinical trials in Amyotrophic lateral sclerosis in USA (unspecified route) before June 2023 (Biolexis Therapeutics pipeline, June 2023)